TOKYO -- Takeda Pharmaceutical's state-of-the-art research and development center in the waterfront city of Shonan has yet to yield a blockbuster treatment since its founding a decade ago -- a weak track record the Japanese drugmaker is determined to improve.
In addition to excessive sleepiness, it can cause hallucinations and could lead to a serious sleep disorder. The number of patients is estimated at around 3 million worldwide. Takeda's eagerness to tout its work on the narcolepsy treatment reflects the hard truth that the 140 billion yen R&D site has not produced a top seller.
Takeda's research site in Cambridge, Massachusetts, is the largest in the group, having overtaken the Shonan facility. Launching a homegrown top seller that will bring in more than 500 billion yen in global sales has been a long-cherished goal of Takeda.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
ソース: YahooNewsTopics - 🏆 79. / 51 続きを読む »
ソース: nikkei - 🏆 135. / 51 続きを読む »